Novasep has made a $5.5m (€4m) investment to expand its highly potent active pharmaceutical ingredients (HPAPI) manufacturing capabilities at its Le Mans facility in France.
Novasep has reported a 14 percent growth in its biopharma business driven in part by demand for downstream manufacturing and its continuous chromatography systems.
Novasep has bolstered its upstream processing capabilities by acquiring Henogen, a Belgium-based CMO that has biotech development and cGMP manufacturing expertise.